Loading the SOTA2 catalog…
iCAD, Inc.
Global leader in AI-powered breast health solutions, now part of DeepHealth, providing clinically proven solutions for cancer detection, density assessment, and personalized risk evaluation.
- Founded
- Not disclosed
- Headquarters
- Not disclosed
- Company size
- Not disclosed
- Products tracked
- 6
Products by iCAD, Inc.
Customer voice
Customer testimonials
Quotes published on iCAD, Inc.'s official website.
My MQSA numbers are the best they’ve ever been. My productivity is as high as it has ever been, with this algorithm and with this suite of tools here. Everybody wants you to do a better job and work faster, and this has allowed me to do it. Mark Traill, MDBreast Radiologist, University of Michigan Health-West
Adopting ProFound AI was straightforward. It increases our comfort level knowing that the technology is reading every image, or slice, and it’s reassuring knowing that this technology will help us not miss a cancer. I typically will read the images without ProFound AI first, just to get a gut impression of the case, but when I turn ProFound AI on, it gives me added peace of mind knowing that the technology will alert me to look at certain images more closely.
Adopting ProFound AI was a seamless process that offered immediate benefits to our radiologists and patients, and we have gained additional efficiencies since then.
Customer outcomes
Case studies
Selected customer stories from iCAD, Inc..
How Cleveland Clinic is Finding the Breast Cancers Radiologists Fear the Most
Read case studyWhy RCI Became the First in the State to Adopt ProFound AI as its Breast AI Solution for Mammography
Read case studyElevating Accuracy with ProFound AI® at Baptist Health South Florida
Read case studyPricing for iCAD, Inc.
Contact sales
Contact iCAD, Inc. for current plans, volume pricing, and enterprise terms.
Trust profile
Security and compliance
No compliance claims have been published for this company.
Latest updates from iCAD, Inc.
Product launch
DeepHealth Receives FDA Clearances for Breast Imaging AI Tools
DeepHealth, a subsidiary of RadNet, Inc., received FDA 510(k) clearances for two new functionalities within its Breast Suite: a Breast Arterial Calcification (BAC) Assessment tool to identify indicators of cardiovascular disease, and prior exam integration for its Mammo Dx platform to improve lesion tracking. These tools are designed to assist radiologists by providing automated assessments during standard breast imaging and are now commercially available in the United States.
